Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease.

scientific article

Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S40620-014-0045-4
P698PubMed publication ID24515315

P50authorIsmail KocyigitQ79364273
Eray ErogluQ83287759
Fahir OzturkQ86628654
Özcan ÖrsçelikQ89439467
Hakan İmamoğluQ91558509
Unal AydinQ94470735
Ozkan GungorQ97594903
Bülent TokgözQ116884257
Murat Hayri SipahiogluQ117241427
Oktay OymakQ117241428
Cigdem KarakukcuQ61106980
P2860cites workAutosomal dominant polycystic kidney diseaseQ72805647
Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parentsQ72888041
Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal functionQ80050909
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular diseaseQ80316793
Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patientsQ84379418
Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney diseaseQ87149663
Autosomal dominant polycystic kidney disease: the last 3 yearsQ24656249
Cardiovascular abnormalities in autosomal-dominant polycystic kidney diseaseQ24657714
Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education ProgramQ28285436
C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studiesQ33312953
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?Q33345061
Hypertension in autosomal dominant polycystic kidney diseaseQ33754691
Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular diseaseQ33997369
PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammationQ34106947
Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul StudyQ34150807
Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes.Q34324823
Inflammation, Oxidative Stress, and Insulin Resistance in Polycystic Kidney DiseaseQ34497281
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomesQ34751855
The clinical implications of endothelial dysfunctionQ35548796
The long pentraxin PTX3 in vascular pathologyQ36615475
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney diseaseQ36736700
Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter?Q37832075
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortalityQ44571381
Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney diseaseQ44581660
Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cellsQ44985116
Pentraxin 3: a novel and independent prognostic marker in ischemic stroke.Q48770462
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.Q53496784
Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease.Q54043582
P433issue2
P921main subjectinflammationQ101991
endotheliumQ111140
autosomal dominant polycystic kidneyQ2732398
autosomal dominant polycystic kidney diseaseQ15443105
P304page(s)181-186
P577publication date2014-02-11
P1433published inJournal of NephrologyQ15765408
P1476titlePentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease
P478volume27

Reverse relations

cites work (P2860)
Q36284659Biomarkers and surrogate endpoints in kidney disease
Q40865321Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function
Q38683930Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness.
Q64104744Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies
Q49909712Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
Q90324149The association of endothelin-1 levels with renal survival in polycystic kidney disease patients
Q47626900Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases

Search more.